Global Ischemic Heart Disease (IHD) Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Disease Class;

Angina Pectoris - Stable Angina, Unstable Angina, and Prinzmetal's Angina, Mi - Stemi, and Nstemi.

By Drug Class;

Anti-dyslipidemic Drugs, Calcium Channel Blockers, Beta-blockers, ACE Inhibitors, ARBs, Vasodilators, and Antithrombotic Agents.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn111162839 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Ischemic Heart Disease (IHD) Drugs Market (USD Million), 2021 - 2031

In the year 2024, the Global Ischemic Heart Disease (IHD) Drugs Market was valued at USD 6,678.45 million. The size of this market is expected to increase to USD 9,091.49 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.5%.

The global ischemic heart disease (IHD) drugs market is witnessing significant growth due to the rising prevalence of cardiovascular diseases worldwide. Ischemic heart disease, characterized by reduced blood flow to the heart muscle, remains a leading cause of morbidity and mortality globally, driving the demand for effective pharmacological interventions.

One of the key drivers of market growth is the increasing adoption of preventive measures and treatment options for managing IHD risk factors such as hypertension, diabetes, and dyslipidemia. Pharmaceutical companies are investing in the development of novel drugs and therapies aimed at reducing the incidence of cardiovascular events and improving patient outcomes. These drugs target various pathways involved in the pathophysiology of IHD, including cholesterol metabolism, blood pressure regulation, and platelet function, offering a diverse range of treatment options for patients with IHD.

The growing geriatric population, coupled with lifestyle changes and unhealthy dietary habits, contributes to the rising burden of ischemic heart disease globally. As a result, there is a growing demand for pharmacological interventions that can effectively manage IHD symptoms, prevent disease progression, and reduce the risk of cardiovascular events such as heart attacks and strokes. Healthcare providers are increasingly prescribing combination therapies and personalized treatment regimens tailored to individual patient needs and comorbidities, driving market expansion in the IHD drugs segment.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Disease Class
    2. Market Snapshot, By Drug Class
    3. Market Snapshot, By Region
  4. Global Ischemic Heart Disease (IHD) Drugs Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Ischemic Heart Disease
        2. Advancements in Drug Development
        3. Growing Geriatric Population
      2. Restraints
        1. Stringent Regulatory Requirements
        2. High Cost of Treatment
        3. Increasing Competition from Generic Drugs
      3. Opportunities
        1. Emerging Markets
        2. Personalized Medicine
        3. Focus on Combination Therapies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Ischemic Heart Disease (IHD) Drugs Market, By Disease Class, 2021 - 2031 (USD Million)
      1. Angina Pectoris
        1. Stable Angina
        2. Unstable Angina
        3. Prinzmetal's Angina
      2. Mi
        1. Stemi
        2. Nstemi
    2. Global Ischemic Heart Disease (IHD) Drugs Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Anti-dyslipidemic Drugs
      2. Calcium Channel Blockers
      3. Beta-blockers
      4. ACE Inhibitors
      5. ARBs
      6. Vasodilators
      7. Antithrombotic Agents
    3. Global Ischemic Heart Disease (IHD) Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AstraZeneca
      2. Bayer
      3. Eli Lilly
      4. Novartis
      5. Pfizer
      6. Sanofi
  7. Analyst Views
  8. Future Outlook of the Market